使用改善病情抗风湿药的系统性自身免疫性风湿病患者接种第四剂COVID-19 mRNA疫苗的有效性:一项模拟目标试验
该模拟目标试验利用Mass General Brigham医疗系统观察性数据,比较接种与未接种第四剂mRNA疫苗的系统性自身免疫性风湿病DMARD使用者的SARS-CoV-2感染风险。纳入4305例患者,接种组3126例,未接种组1179例。接种第四剂使SARS-CoV-2感染风险降低(HR 0.59,95%CI 0.47-0.74),并使感染后-3至+14天内住院或死亡风险降低(HR 0.35,95%CI 0.14-0.85)。
要点
- 接种第四剂mRNA疫苗与SARS-CoV-2感染风险降低相关(HR 0.59,95%CI 0.47-0.74)。
- 第四剂使SARS-CoV-2感染后-3至+14天内住院或死亡风险降低(HR 0.35,95%CI 0.14-0.85)。
- 作者认为应鼓励系统性自身免疫性风湿病患者及时接种COVID-19疫苗。
核心结论
- 在Omicron时代,第四剂COVID-19 mRNA疫苗降低了使用DMARD的系统性自身免疫性风湿病患者的SARS-CoV-2感染风险和重症COVID-19风险。
- 作者认为应鼓励系统性自身免疫性风湿病患者及时接种COVID-19疫苗。
研究设计与样本
- 采用模拟目标试验设计,利用Mass General Brigham医疗系统的观察性数据,比较接种与未接种第四剂mRNA疫苗。
- 分析对象为患有系统性自身免疫性风湿病、正在使用DMARD、且在2022年1月16日至6月11日期间符合第四剂BNT162b2或mRNA-1273疫苗接种条件的患者。
- 研究期间按1周间隔分层;第四剂暴露组为在该周内接种第四剂mRNA疫苗者,非暴露组为符合条件但未接种第四剂者。
- 主要结局为SARS-CoV-2感染;次要结局为重症SARS-CoV-2感染(即阳性检测前后-3至+14天内住院或死亡)。
- 采用时间分层、重叠倾向评分加权Cox回归模型评估第四剂有效性。
主要发现
- 共纳入4305例患者,其中3126例接种第四剂疫苗,1179例未接种。
- 接种第四剂组中位随访135天(IQR 112-154),未接种第四剂组中位随访65天(IQR 30-156)。
- 重叠加权后,2563例参与者中女性1863例(72.7%)、男性700例(27.3%),白人2242例(87.5%)。
- 2563例参与者中类风湿关节炎1392例(54.3%);最常见治疗为传统合成DMARD(1489例[58.1%])或生物DMARD(1007例[39.3%])。
- 接种第四剂组较未接种组SARS-CoV-2感染风险更低(HR 0.59 [95%CI 0.47-0.74]),且第四剂降低SARS-CoV-2感染后-3至+14天内住院或死亡风险(HR 0.35 [95%CI 0.14-0.85])。
临床怎么用
- 作者认为应鼓励使用DMARD的系统性自身免疫性风湿病患者及时接种COVID-19疫苗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with systemic autoimmune rheumatic diseases using disease-modifying antirheumatic drugs (DMARDs) might have blunted responses to COVID-19 vaccines. The initial mRNA vaccine series is defined as three doses for this population and a fourth booster dose is recommended. The effectiveness of the fourth dose in patients with systemic autoimmune rheumatic diseases using DMARDs is not well established. We aimed to assess the effectiveness of receiving versus not receiving a fourth dose of COVID-19 mRNA vaccine using a target trial framework, in a cohort of patients with systemic autoimmune rheumatic diseases receiving DMARD therapy. METHODS: We conducted an emulated target trial using observational data from the Mass General Brigham health-care system to compare receiving versus not receiving a fourth mRNA vaccine dose. Analysed patients had systemic autoimmune rheumatic diseases, were prescribed DMARDs, and were eligible for a fourth dose of BNT162b2 or mRNA-1273 vaccines between Jan 16 and June 11, 2022. To account for temporal changes, the study period was divided into 1-week intervals. Fourth-dose-exposed patients were included in a 1-week interval if they received a fourth mRNA dose in that interval; fourth-dose-unexposed patients were eligible for but had not received the fourth dose of the vaccine. The primary outcome was a SARS-CoV-2 infection; the secondary outcome was severe SARS-CoV-2 infection (ie, admission to hospital or death within -3 to +14 days of a positive test). We assessed the effectiveness of the fourth dose using time-stratified, overlap propensity score-weighted Cox regression models. FINDINGS: We included 4305 patients, 3126 of whom received a fourth dose of vaccine and 1179 who had not. The median follow-up time was 135 days (IQR 112-154) among patients who had received a fourth dose and 65 days (30-156) among patients who had not received a fourth dose. After overlap weighting in both groups, 1863 (72·7%) of 2563 participants were women, 700 (27·3%) were men, and 2242 (87·5%) were White. Rheumatoid arthritis was present in 1392 (54·3%) of 2563 participants; the most frequent treatments were conventional synthetic DMARDs (1489 [58·1%]) or biological DMARDs (1007 [39·3%]). SARS-CoV-2 infection risk was lower among patients receiving versus not receiving a fourth dose of vaccine (HR 0·59 [95% CI 0·47-0·74]). A fourth dose reduced the risk of admission to hospital or death within -3 to +14 days of SARS-CoV-2 infection (0·35 [0·14-0·85]). INTERPRETATION: In this emulated target trial, a fourth dose of COVID-19 mRNA vaccine reduced the risk of SARS-CoV-2 infection and severe COVID-19 among patients with systemic autoimmune rheumatic diseases using DMARDs during the Omicron era. Patients with systemic autoimmune rheumatic diseases should be encouraged to remain up-to-date with COVID-19 vaccinations. FUNDING: The National Institutes of Health and the National Institute of Arthritis and Musculoskeletal and Skin Diseases.
引用
- Hanberg JS, Fu X, Wang X, et al. Effectiveness of a fourth dose of COVID-19 mRNA vaccine in patients with systemic autoimmune rheumatic diseases using disease-modifying antirheumatic drugs: an emulated target trial. Lancet Rheumatol. 2023. PMID: 38258675. doi:10.1016/S2665-9913(23)00272-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。